Gilead Finalizes Deal With Global Fund To Supply Lenacapavir At Cost To Low-Income Countries

Reuters (7/9, Beasley, Rigby) reports that Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria announced Wednesday that “they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the absence of funding from a key U.S. initiative aimed at addressing the global HIV/AIDS epidemic.” Gilead agreed to supply, at cost, enough doses of lenacapavir “to reach up to 2 million people over three years in countries supported by the Global Fund. Both parties said price terms are confidential, and the Global Fund declined to comment further on how many doses would be ordered immediately.” Gilead last year “signed royalty-free deals allowing six generic drugmakers to make and sell low-cost versions of the drug in 120 low- and middle-income countries, but those supplies will take time to get up and running.”